Equities Analysts Offer Predictions for AstraZeneca PLC’s FY2025 Earnings (NASDAQ:AZN)

AstraZeneca PLC (NASDAQ:AZN) – Equities researchers at Zacks Research lifted their FY2025 EPS estimates for AstraZeneca in a research note issued to investors on Thursday, September 26th. Zacks Research analyst R. Department now anticipates that the company will post earnings of $4.54 per share for the year, up from their prior forecast of $4.53. The consensus estimate for AstraZeneca’s current full-year earnings is $4.05 per share. Zacks Research also issued estimates for AstraZeneca’s Q1 2026 earnings at $1.18 EPS and FY2026 earnings at $5.06 EPS.

Several other equities research analysts also recently commented on AZN. Barclays upgraded shares of AstraZeneca to a “strong-buy” rating in a research note on Monday, June 24th. TD Cowen lifted their price target on AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a report on Monday, August 12th. Citigroup raised AstraZeneca to a “strong-buy” rating in a report on Monday, June 24th. Deutsche Bank Aktiengesellschaft cut AstraZeneca from a “hold” rating to a “sell” rating in a report on Friday, September 13th. Finally, Erste Group Bank raised AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. One analyst has rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $89.75.

AstraZeneca Stock Up 1.0 %

Shares of NASDAQ:AZN opened at $78.67 on Monday. AstraZeneca has a 52 week low of $60.47 and a 52 week high of $87.68. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.89. The company’s fifty day moving average is $81.65 and its 200-day moving average is $77.26. The company has a market capitalization of $243.92 billion, a PE ratio of 38.56, a P/E/G ratio of 1.47 and a beta of 0.47.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings results on Thursday, July 25th. The company reported $0.99 earnings per share for the quarter, topping analysts’ consensus estimates of $0.98 by $0.01. AstraZeneca had a net margin of 13.11% and a return on equity of 29.34%. The firm had revenue of $12.45 billion for the quarter, compared to the consensus estimate of $12.62 billion. During the same quarter in the previous year, the company earned $1.08 earnings per share. The business’s revenue was up 9.1% compared to the same quarter last year.

Institutional Trading of AstraZeneca

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Centaurus Financial Inc. bought a new stake in shares of AstraZeneca in the 2nd quarter valued at about $182,000. Healthcare of Ontario Pension Plan Trust Fund grew its position in shares of AstraZeneca by 38,185.0% in the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 53,599 shares of the company’s stock valued at $4,180,000 after purchasing an additional 53,459 shares during the period. Point72 Asia Singapore Pte. Ltd. grew its position in shares of AstraZeneca by 122.4% in the 2nd quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,728 shares of the company’s stock valued at $135,000 after purchasing an additional 951 shares during the period. American Trust grew its position in shares of AstraZeneca by 27.9% in the 2nd quarter. American Trust now owns 4,387 shares of the company’s stock valued at $342,000 after purchasing an additional 957 shares during the period. Finally, Heritage Wealth Management Inc. acquired a new position in shares of AstraZeneca in the 2nd quarter valued at approximately $688,000. 20.35% of the stock is owned by institutional investors.

AstraZeneca Cuts Dividend

The business also recently declared a Semi-Annual dividend, which was paid on Monday, September 9th. Stockholders of record on Friday, August 9th were paid a $0.49 dividend. The ex-dividend date of this dividend was Friday, August 9th. This represents a dividend yield of 1.8%. AstraZeneca’s dividend payout ratio (DPR) is presently 48.04%.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.